These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden. Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A; J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995 [TBL] [Abstract][Full Text] [Related]
27. [Bacterial infections of the lungs in mucoviscidosis patients]. Hogardt M; Heesemann J MMW Fortschr Med; 2005 Jan; 147(4):38-40. PubMed ID: 15745340 [TBL] [Abstract][Full Text] [Related]
28. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients. Westerman EM; Heijerman HG; Frijlink HW Expert Opin Drug Deliv; 2007 Mar; 4(2):91-4. PubMed ID: 17335406 [TBL] [Abstract][Full Text] [Related]
29. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland. Stelmach I; Korzeniewska A; Stelmach W Respiration; 2008; 75(2):178-81. PubMed ID: 17435382 [TBL] [Abstract][Full Text] [Related]
30. Developmental paradigm for early features of cystic fibrosis. Larson JE; Cohen JC Pediatr Pulmonol; 2005 Nov; 40(5):371-7. PubMed ID: 15830387 [TBL] [Abstract][Full Text] [Related]
32. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy. Kerem E Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796 [TBL] [Abstract][Full Text] [Related]
33. Cystic fibrosis: ironing out the problem of infection? Reid DW; Anderson GJ; Lamont IL Am J Physiol Lung Cell Mol Physiol; 2008 Jul; 295(1):L23-4. PubMed ID: 18487353 [No Abstract] [Full Text] [Related]
35. New drugs for cystic fibrosis. Wilschanski M; Kerem E Expert Opin Investig Drugs; 2011 Sep; 20(9):1285-92. PubMed ID: 21745147 [TBL] [Abstract][Full Text] [Related]
36. [Cystic fibrosis. Current indications for nebulized treatments: antibiotics and DNase]. Sardet-Frismand A Rev Mal Respir; 1999 Jan; 16 Suppl 3():S131-2. PubMed ID: 10088286 [No Abstract] [Full Text] [Related]
37. Tobramycin is a suppressor of premature termination codons. Altamura N; Castaldo R; Finotti A; Breveglieri G; Salvatori F; Zuccato C; Gambari R; Panin GC; Borgatti M J Cyst Fibros; 2013 Dec; 12(6):806-11. PubMed ID: 23540394 [TBL] [Abstract][Full Text] [Related]
38. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142 [TBL] [Abstract][Full Text] [Related]
39. Neutrophilic inflammation as a major determinant in the progression of cystic fibrosis. Tirouvanziam R Drug News Perspect; 2006 Dec; 19(10):609-14. PubMed ID: 17299603 [TBL] [Abstract][Full Text] [Related]
40. Aquagenic wrinkling of the palms in an adult cystic fibrosis population. Tolland JP; Boyle J; Hall V; McKenna KE; Elborn JS Dermatology; 2010; 221(4):326-30. PubMed ID: 20881360 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]